A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nektar Therapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 12,800 shares of NKTR stock, worth $12,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,800
Previous 1,900 573.68%
Holding current value
$12,800
Previous $2,000 700.0%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $3.39 Million - $6.88 Million
3,761,256 Added 117.77%
6,954,970 $8.62 Million
Q1 2024

May 15, 2024

SELL
$0.49 - $0.96 $1.19 Million - $2.33 Million
-2,431,286 Reduced 43.22%
3,193,714 $2.97 Million
Q3 2023

Nov 14, 2023

SELL
$0.51 - $1.05 $2.08 Million - $4.28 Million
-4,078,652 Reduced 42.03%
5,625,000 $3.38 Million
Q2 2023

Aug 14, 2023

BUY
$0.53 - $1.03 $3.63 Million - $7.05 Million
6,840,582 Added 238.92%
9,703,652 $5.63 Million
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $627,642 - $3.09 Million
980,692 Added 52.1%
2,863,070 $2 Million
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $1.37 Million - $2.9 Million
677,216 Added 56.19%
1,882,378 $4.25 Million
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $2.21 Million - $3.74 Million
726,812 Added 151.94%
1,205,162 $3.86 Million
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $1.68 Million - $3.28 Million
-531,244 Reduced 52.62%
478,350 $1.82 Million
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $3.45 Million - $11.4 Million
828,363 Added 457.08%
1,009,594 $5.44 Million
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $931,315 - $1.58 Million
85,994 Added 90.29%
181,231 $2.45 Million
Q3 2021

Nov 15, 2021

SELL
$13.07 - $18.84 $252,433 - $363,875
-19,314 Reduced 16.86%
95,237 $1.71 Million
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $168,570 - $208,161
10,204 Added 9.78%
114,551 $1.97 Million
Q1 2021

May 17, 2021

BUY
$16.56 - $25.46 $1.22 Million - $1.87 Million
73,534 Added 238.65%
104,347 $2.09 Million
Q4 2020

Feb 16, 2021

SELL
$15.77 - $19.03 $4.09 Million - $4.93 Million
-259,288 Reduced 89.38%
30,813 $524,000
Q3 2020

Nov 16, 2020

SELL
$16.59 - $24.79 $3.45 Million - $5.15 Million
-207,826 Reduced 41.74%
290,101 $4.81 Million
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $376,770 - $523,813
22,347 Added 4.7%
497,927 $11.5 Million
Q1 2020

May 15, 2020

BUY
$14.47 - $27.96 $3.66 Million - $7.07 Million
252,835 Added 113.51%
475,580 $8.49 Million
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $1.13 Million - $1.64 Million
71,087 Added 46.87%
222,745 $4.81 Million
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $656,868 - $1.41 Million
38,845 Added 34.43%
151,658 $2.76 Million
Q2 2019

Aug 14, 2019

SELL
$31.0 - $36.3 $5.94 Million - $6.96 Million
-191,755 Reduced 62.96%
112,813 $4.01 Million
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $6.97 Million - $10.2 Million
-220,612 Reduced 42.01%
304,568 $0
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $13.6 Million - $25.3 Million
446,944 Added 571.28%
525,180 $17.3 Million
Q3 2018

Nov 13, 2018

SELL
$46.46 - $68.49 $16 Million - $23.6 Million
-344,861 Reduced 81.51%
78,236 $0
Q2 2018

Aug 10, 2018

BUY
$46.25 - $104.45 $19.5 Million - $44 Million
421,012 Added 20192.42%
423,097 $0
Q1 2018

May 11, 2018

SELL
$57.4 - $108.44 $1.55 Million - $2.92 Million
-26,941 Reduced 92.82%
2,085 $222,000
Q4 2017

Feb 09, 2018

SELL
$23.02 - $60.5 $2.07 Million - $5.44 Million
-89,917 Reduced 75.6%
29,026 $1.73 Million
Q3 2017

Nov 09, 2017

BUY
$17.79 - $24.0 $2.12 Million - $2.85 Million
118,943
118,943 $2.86 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $187M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.